ICYMI: FDA In Favor Of Luxturna, A Gene Therapy For Leber Congenital Amaurosis
Source: Pixabay

ICYMI: FDA In Favor Of Luxturna, A Gene Therapy For Leber Congenital Amaurosis

The FDA, US Food and Drug Administration, unanimously agreed upon the recommendation for a new gene therapy that treats a rare form of blindness, reported ScienceNordic. Spark Therapeutics, a biotech…

Continue Reading ICYMI: FDA In Favor Of Luxturna, A Gene Therapy For Leber Congenital Amaurosis